{"pmid":32343415,"title":"Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients.","text":["Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19) has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms and no case of severe symptoms was found among these patients. Strikingly, a subset of these patients had SRAS-CoV-2 and virus-specific IgG coexist for an unexpectedly long time, with two cases for up to 50 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity alone may still be powerful enough to eliminate SARS-CoV-2. This report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in non-severe cases. This article is protected by copyright. All rights reserved.","J Med Virol","Wang, Bin","Wang, Li","Kong, Xianggen","Geng, Jin","Xiao, Di","Ma, Chunhong","Jiang, Xue-Mei","Wang, Pei-Hui","32343415"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19) has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms and no case of severe symptoms was found among these patients. Strikingly, a subset of these patients had SRAS-CoV-2 and virus-specific IgG coexist for an unexpectedly long time, with two cases for up to 50 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity alone may still be powerful enough to eliminate SARS-CoV-2. This report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in non-severe cases. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Wang, Bin","Wang, Li","Kong, Xianggen","Geng, Jin","Xiao, Di","Ma, Chunhong","Jiang, Xue-Mei","Wang, Pei-Hui"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32343415","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25946","keywords":["antibody","covid-19","igg","immunity","sars-cov-2"],"locations":["Jinan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1665351883825348609,"score":8.574329,"similar":[{"pmid":32267987,"title":"Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.","text":["Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS.","The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future.","Rev Med Virol","Rokni, Mohsen","Ghasemi, Vida","Tavakoli, Zahra","32267987"],"abstract":["The beginning of 2020 has seen the emergence of COVID-19, an outbreak caused by a novel coronavirus, SARS-CoV-2, an important pathogen for humans. There is an urgent need to better understand this new virus and to develop ways to control its spread. In Iran, the first case of the COVID-19 was reported after spread from China and other countries. Fever, cough, and fatigue were the most common symptoms of this virus. In worldwide, the incubation period of COVID-19 was 3 to 7 days and approximately 80% of infections are mild or asymptomatic, 15% are severe, requiring oxygen, and 5% are critical infections, requiring ventilation. To mount an antiviral response, the innate immune system recognizes molecular structures that are produced by the invasion of the virus. COVID-19 infection induces IgG antibodies against N protein that can be detected by serum as early as day 4 after the onset of disease and with most patients seroconverting by day 14. Laboratory evidence of clinical patients showed that a specific T-cell response against SARS-CoV-2 is important for the recognition and killing of infected cells, particularly in the lungs of infected individuals. At present, there is no specific antiviral therapy for COVID-19 and the main treatments are supportive. In this review, we investigated the innate and acquired immune responses in patients who recovered from COVID-19, which could inform the design of prophylactic vaccines and immunotherapy for the future."],"journal":"Rev Med Virol","authors":["Rokni, Mohsen","Ghasemi, Vida","Tavakoli, Zahra"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267987","week":"202015|Apr 06 - Apr 12","doi":"10.1002/rmv.2107","keywords":["2019-ncov disease","b cell","covid-19","sars-cov-2","t cell","coronavirus","immunity"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Iran","China","Iran"],"countries":["China","Iran, Islamic Republic of"],"countries_codes":["CHN|China","IRN|Iran, Islamic Republic of"],"_version_":1664637635953426432,"score":469.5151},{"pmid":32330303,"title":"Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","text":["Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.","Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang","32330303"],"abstract":["Coronavirus disease (COVID-19), caused by a novel betacoronavirus, SARS-CoV-2, has rapidly developed into a pandemic since it was first reported in December 2019. Nucleic acid testing is the standard method for the diagnosis of viral infections. However, this method reportedly has a low positivity rate. To increase the sensitivity of COVID-19 diagnoses, we developed an IgM-IgG combined assay and tested it in patients with suspected SARS-CoV-2 infection. In total, 56 patients were enrolled in this study and SARS-CoV-2 was detected by using both IgM-IgG antibody and nucleic acid tests. Clinical and laboratory data were collected and analyzed. Our findings suggest that patients who develop severe illness might experience longer virus exposure times and develop a more severe inflammatory response. The IgM-IgG test is an accurate and sensitive diagnostic method. A combination of nucleic acid and IgM-IgG testing is a more sensitive and accurate approach for diagnosis and early treatment of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Xie, Jiajia","Ding, Chengchao","Li, Jing","Wang, Yulan","Guo, Hui","Lu, Zhaohui","Wang, Jinquan","Zheng, Changcheng","Jin, Tengchuan","Gao, Yong","He, Hongliang"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330303","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25930","keywords":["covid-19","igg","igm","sars-cov-2","diagnosis"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664996914758680576,"score":343.10583},{"pmid":32221519,"title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.","text":["Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.","BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. METHODS: A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. RESULTS: Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006). CONCLUSIONS: The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.","Clin Infect Dis","Zhao, Juanjuan","Yuan, Quan","Wang, Haiyan","Liu, Wei","Liao, Xuejiao","Su, Yingying","Wang, Xin","Yuan, Jing","Li, Tingdong","Li, Jinxiu","Qian, Shen","Hong, Congming","Wang, Fuxiang","Liu, Yingxia","Wang, Zhaoqin","He, Qing","Li, Zhiyong","He, Bin","Zhang, Tianying","Fu, Yang","Ge, Shengxiang","Liu, Lei","Zhang, Jun","Xia, Ningshao","Zhang, Zheng","32221519"],"abstract":["BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated. METHODS: A total of 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n=535) collected during the hospitalization were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2. The dynamics of antibodies with the disease progress was analyzed. RESULTS: Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1%, 82.7% and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might due to the lack of blood samples at the later stage of illness. The median seroconversion time for Ab, IgM and then IgG were day-11, day-12 and day-14, separately. The presence of antibodies was <40% among patients within 1-week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) since day-15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) during day 15-39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (p<0.001), even in early phase of 1-week since onset (p=0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p=0.006). CONCLUSIONS: The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients."],"journal":"Clin Infect Dis","authors":["Zhao, Juanjuan","Yuan, Quan","Wang, Haiyan","Liu, Wei","Liao, Xuejiao","Su, Yingying","Wang, Xin","Yuan, Jing","Li, Tingdong","Li, Jinxiu","Qian, Shen","Hong, Congming","Wang, Fuxiang","Liu, Yingxia","Wang, Zhaoqin","He, Qing","Li, Zhiyong","He, Bin","Zhang, Tianying","Fu, Yang","Ge, Shengxiang","Liu, Lei","Zhang, Jun","Xia, Ningshao","Zhang, Zheng"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221519","week":"202014|Mar 30 - Apr 05","doi":"10.1093/cid/ciaa344","keywords":["covid-19","sars-cov-2","antibody"],"source":"PubMed","topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1664638629646958592,"score":330.7531},{"pmid":32330293,"title":"Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection.","text":["Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection.","As an emerging infectious disease, the clinical course and virological course of SARS-CoV-2 infection remain to be further investigated. In this case report, we described a case of SARS-CoV-2 infection with clinical course more than two months. This patient had recovered from the pneumonia after treatment. The viral RNA of throat swabs became negative and the viral specific antibodies were produced during recovery period. However, the viral RNA reappeared and additionally persisted in throat swabs for more than 40 days. In addition, the viral RNA was detected in multiple types of specimens with extremely high titers in the saliva. In conclusion, these findings indicate that SARS-CoV-2 can cause a long clinical course. The coexistence of viral RNA and viral specific antibodies may imply an immune evasion of SARAS-CoV-2 from host's immune system. This article is protected by copyright. All rights reserved.","J Med Virol","Yang, Jian-Rong","Deng, Dao-Ting","Wu, Nan","Yang, Bin","Li, Hong-Juan","Pan, Xiao-Ben","32330293"],"abstract":["As an emerging infectious disease, the clinical course and virological course of SARS-CoV-2 infection remain to be further investigated. In this case report, we described a case of SARS-CoV-2 infection with clinical course more than two months. This patient had recovered from the pneumonia after treatment. The viral RNA of throat swabs became negative and the viral specific antibodies were produced during recovery period. However, the viral RNA reappeared and additionally persisted in throat swabs for more than 40 days. In addition, the viral RNA was detected in multiple types of specimens with extremely high titers in the saliva. In conclusion, these findings indicate that SARS-CoV-2 can cause a long clinical course. The coexistence of viral RNA and viral specific antibodies may imply an immune evasion of SARAS-CoV-2 from host's immune system. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Yang, Jian-Rong","Deng, Dao-Ting","Wu, Nan","Yang, Bin","Li, Hong-Juan","Pan, Xiao-Ben"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330293","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25940","keywords":["coronavirus","sars-cov-2","saliva","virus shedding"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664996914958958594,"score":329.1838},{"pmid":32229257,"title":"Risk-adapted Treatment Strategy For COVID-19 Patients.","text":["Risk-adapted Treatment Strategy For COVID-19 Patients.","BACKGROUND: There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease (COVID-19). The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19. METHODS: We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity. RESULTS: Twelve patients were in mild group and 22 were in moderate group (non-severe group, n=34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p=0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 RNA clearance between two group (p=0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p=0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis. CONCLUSIONS: Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of low-dose methylprednisolone was beneficial and did not delay SARS-CoV-2 RNA clearance and influence IgG antibody production.","Int J Infect Dis","Zheng, Changcheng","Wang, Jinquan","Guo, Hui","Lu, Zhaohui","Ma, Yan","Zhu, Yuyou","Xia, Daqing","Wang, Yinzhong","He, Hongliang","Zhou, Jian","Wang, Yong","Fei, Mingming","Yin, Yihong","Zheng, Mao","Xu, Yehong","32229257"],"abstract":["BACKGROUND: There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease (COVID-19). The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19. METHODS: We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity. RESULTS: Twelve patients were in mild group and 22 were in moderate group (non-severe group, n=34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p=0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 RNA clearance between two group (p=0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p=0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis. CONCLUSIONS: Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of low-dose methylprednisolone was beneficial and did not delay SARS-CoV-2 RNA clearance and influence IgG antibody production."],"journal":"Int J Infect Dis","authors":["Zheng, Changcheng","Wang, Jinquan","Guo, Hui","Lu, Zhaohui","Ma, Yan","Zhu, Yuyou","Xia, Daqing","Wang, Yinzhong","He, Hongliang","Zhou, Jian","Wang, Yong","Fei, Mingming","Yin, Yihong","Zheng, Mao","Xu, Yehong"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32229257","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijid.2020.03.047","keywords":["covid-19","antiviral treatment","low-dose corticosteroid","novel coronavirus pneumonia","risk-adapted treatment strategy"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Methylprednisolone"],"_version_":1664638455260381185,"score":323.39896}]}